Co-targeting studies of CD19/BCMA showcased a robust overall response rate of 95%, accompanied by complete response rates ranging from 16% to 57% (35) Similarly in lymphoma combinations of CD19 with CD22 are under study (36). This evidence concerns the gene CD19 and lymphoma.